louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06265792: Efficacy of Stellate Ganglion Block in Obstructive Sleep Apnea
Official title: A Randomized Controlled Trial to Explore the Efficacy of Stellate Ganglion Block in Obstructive Sleep Apnea
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Obstructive Sleep Apnea
Lead sponsor: People's Hospital of Zhengzhou University
Sponsor class: OTHER
First posted: 2024-02-20
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are:

• Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

Detailed description: Obstructive Sleep Apnea is of increasingly high prevalence.

The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are:

• Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

Eligibility criteria: Inclusion Criteria:

* Patients aged over 18 years diagnosed with OSA by polysomnography
* Patients with moderate to severe OSA (AHI \> 15 events per hour)
* Patients who have undergone continuous positive airway pressure (CPAP) treatment for at least 3 months but have not achieved satisfactory therapeutic effects
* Patients who voluntarily agree to receive stellate ganglion block (SGB) treatment and sign the informed consent form

Exclusion Criteria:

* Patients with a history of allergy or contraindications to local anesthetics or corticosteroids
* Patients with severe cardiovascular, cerebrovascular, respiratory, hepatic, or renal diseases
* Patients with a history of neck surgery or cervical spine disease
* Patients with psychiatric disorders or other medical conditions that may affect the safety or effectiveness of SGB treatment
* Pregnant or lactating women
* Patients who have participated in other clinical trials within the past 3 months

Primary outcomes:
measure: Epworth Sleepiness Scale
timeFrame: day 1 and day 20
Secondary outcomes:
measure: Apnea-Hypopnea Index
timeFrame: day 1 and day 20
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Center Rehabilitation Hospital
Study officials:
affiliation: Site Coordinator of United Medical Group located in Miami
name: Nieto Luis, Doctor
role: STUDY_CHAIR
References:
Clinical trial NCT06153992: Clinical Application of Portable Intelligent Multi Joint Isokinetic Training and Evaluation System Technology
Official title: Clinical Application of Portable Intelligent Multi Joint Isokinetic Training and Evaluation System Technology
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stroke
Hemiplegia
Rehabilitation; Tobacco Use
Physical Disability
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2023-12-01
Enrollment: 90
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to compare in describeparticipant population. The main question it aims to answer is:By using intelligent portable isokinetic tester and traditional isokinetic tester, isokinetic knee flexor and extensor muscles of stroke patients with hemiplegia were trained respectively, so as to observe and compare the effects of the two treatment methods. In addition, the therapeutic effect of the above two treatments was compared with that of exercise therapy alone. Participants will be divided into three groups: control group, intelligent isokinetic treatment group, and traditional isokinetic treatment group. Participants of both the control group and the two treatment groups received exercise therapy. On the basis of exercise therapy, participants of the intelligent isokinetic treatment group used the intelligent portable isokinetic tester to train the affected knee flexion and extensor muscle, while the participants of traditional isokinetic treatment group used the intelligent portable isokinetic tester to train the affected knee flexion and extensor muscle.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Cerebral apoplexy's Disease
* Confirmed by CT or MR Examination of the head
* First onset, duration ≤1 month
* The lower extremity of the hemiplegic limb was above Brunnstrom stage III
* Must be able to sign the informed consent form

Exclusion Criteria:

* Vital signs are unstable
* Severe cognitive, visual and hearing impairment
* Orthopaedic disease
* Muscle pain lower extremity
* Congenital disease
* History of other encephalopathy
* History of mental illness

Primary outcomes:
measure: Body function
timeFrame: up to 1 month
measure: Measured peak moment
timeFrame: up to 1 month
Secondary outcomes:
measure: Satisfaction questionnaire survey
timeFrame: up to 1 month
Other outcomes:
Locations:
city: Jinan
country: China
facility: Intelligent Multi Joint Isokinetic
state: Shandong
Study officials:
affiliation: Qianfoshan Hospital
name: Sanyuan Hu, doctor
role: STUDY_CHAIR
References:
Clinical trial NCT01750892: Primary Care Transition Study
Official title: Transition From Pediatric to Adult Services: A Primary Care Based Model for Patients With Chronic Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Health Condition
Cognitive Disability
Lead sponsor: Children's Hospital of Philadelphia
Sponsor class: OTHER
First posted: 2012-12-17
Enrollment: 43
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study is looking at ways to help young people with chronic health conditions take better care of their health and find an adult doctor.

Detailed description: The purpose of this study is to determine whether providing targeted transition-related skills through interventions with varying degrees of intensity (from the low intensity Basic intervention group, to the mild intensity Group Intervention group, to the high intensity Full Intervention group) results in improved transition readiness and self-care skills and improved successful transition to adult-based services for young adults with chronic health conditions. Secondary objectives include determining if the transition interventions enhance transition-related satisfaction among participants, their caregivers and the involved pediatric and adult providers.

Eligibility criteria: Young Adult Inclusion Criteria:

* Males or females age 19 years of age or older
* Presence of at least 1 Chronic Condition and/or Cognitive Disability
* Last visit with pediatric primary care provider occurring on or after January 1, 2011
* Currently active in one of four identified pediatric practices (Cobbs Creek, Chestnut Hill, Market Street, West Chester)
* Current primary care provider approval for participation
* English speaking

Young Adult Exclusion Criteria:

* Male or female age \< 19 years
* No presence of a chronic condition or cognitive disability
* Last visit with pediatric PCP occurring prior to January 1, 2011
* Not currently active in one of four identified pediatric practices (Cobbs Creek, Chestnut Hill, Market Street, West Chester)
* Current PCP disapproves participation
* Non-English speaking

Caregiver Inclusion Criteria:

* Has a child enrolled in the study
* Child has consented/assented to allow them to participate
* English speaking

Caregiver Exclusion Criteria:

* Child did not consent/assent to allow them to participate
* Non-English speaking

Primary outcomes:
measure: Successful transition to an adult provider
timeFrame: 10 months
Secondary outcomes:
measure: Increased self-care and transition related skills
timeFrame: 6 months
Other outcomes:
measure: Participant satisfaction with the intervention
timeFrame: 6 months
Locations:
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
Study officials:
affiliation: Children's Hospital of Philadelphia
name: Nadja Peter, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Children's Hospital of Philadelphia
name: Oana Tomescu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05520892: Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children
Official title: A Multicenter, Randomized Controlled Study of Two Regimens of Intravenous Immune Globulin in the Treatment of Newly Diagnosed Immune Thrombocytopenia in Children
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment
Lead sponsor: Fujian Medical University Union Hospital
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital of Xiamen University
name: Zhangzhou Affiliated Hospital of Fujian Medical University
name: Quanzhou First Hospital
name: Nanping First Hospital Affiliated to Fujian Medical University
name: The Second Hospital of Anhui Medical University
name: The Affiliated Hospital Of Guizhou Medical University
name: Longyan City First Hospital
name: The Affiliated Hospital of Putian University
First posted: 2022-08-30
Enrollment: 580
Sex: ALL
Minimum age (years): 29
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate


Eligibility criteria: Inclusion Criteria:Subjects enrolled in this study must meet all of the following criteria:

1. Meet the diagnostic criteria of ITP and be diagnosed for the first time without treatment
2. Age \> 28 days and ≤ 14 years old
3. PLT\<20×109/L
4. Have signed the informed consent

Exclusion Criteria:Anyone who has any of the following conditions will not enter the clinical study:

1. Intracranial hemorrhage or severe gastrointestinal or urinary tract hemorrhage requiring emergency treatment, such as simultaneous use of platelet transfusion and glucocorticoid therapy
2. Received glucocorticoid or IVIG therapy within 6 months
3. Weight \> 40kg
4. Menstrual female patients
5. Patients with underlying diseases such as tumor diseases, autoimmune diseases or genetic diseases
6. Patients who have received radiotherapy and chemotherapy
7. There are any significant abnormal coexisting diseases or mental illnesses that affect the patient's life safety and compliance, and affect informed consent, research participation, follow-up or interpretation of results -

Primary outcomes:
measure: early response to treatment
timeFrame: 7 days after treatment
Secondary outcomes:
measure: Economic Indicators
timeFrame: 1 week
measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
timeFrame: 1 week
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: Children with newly dignosed ITP
state: Fujian
Study officials:
References:
Clinical trial NCT02001792: Patient Positioning During Colonoscopy: Effects on Safety and Diagnostic Outcome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sedation Problems
Breathing Complications
Keywords: sedation
endoscopy
patient positioning
hypoxemia
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2013-12-05
Enrollment: 412
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine the effects of patient positioning during colonoscopy on patient safety and diagnostic outcome.

Detailed description: Sedative drugs are widely-used during endoscopic procedures. The administration of these drugs contain the potential hazard of breathing and cardiac complications. Moreover it is well-known that the dorsal position is in some ways associated to breathing problems while patients are asleep. We assume this also to be true related to short anesthesia during colonoscopy. Patient positioning may therefore have a positive effect on the safety during colonoscopy by reducing the absolute time that sedated patients spend in a supine position. We compiled a randomized trial which compares the appearance of breathing and cardiovascular complications by performing colonoscopy either in a dorsal or in a left lateral position.

Eligibility criteria: Inclusion Criteria:

* colonoscopy indicated

Exclusion Criteria:

* patient denies sedation
* prior saturation \< 90%
* prior heart rate \< 50 bpm
* prior blood pressure \< 90 mmHg

Primary outcomes:
measure: frequency of breathing and cardiac problems (decrease of saturation, hypotension, bradycardia) during colonoscopy
timeFrame: participants will be followed for the duration of colonoscopy during hospital stay an expected average of 1 hour
Secondary outcomes:
measure: Adenoma detection rate
timeFrame: 1 day
Other outcomes:
Locations:
city: Munich
country: Germany
facility: Endoscopy Section, Department for Internal Medicine and Gastroenterology, Technical University Munich
state: Bavaria
city: Prien
country: Germany
facility: Krankenhaus Prien
state: Bavaria
Study officials:
affiliation: Departmet for Internal Medicine and Gastroenterology, Technical University Munich, Germany
name: Peter Klare, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Departmet for Internal Medicine and Gastroenterology, Technical University Munich, Germany
name: Stefan von Delius, PD MD
role: STUDY_DIRECTOR
References:
citation: Klare P, Huth R, Haller B, Huth M, Weber A, Schlag C, Reindl W, Schmid RM, von Delius S. Patient position and hypoxemia during propofol sedation for colonoscopy: a randomized trial. Endoscopy. 2015 Dec;47(12):1159-66. doi: 10.1055/s-0034-1392329. Epub 2015 Jun 30.
Clinical trial NCT05312892: Sympathetic Mechanisms in Obesity-Crossover Design
Official title: Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Obesity
Hypertension
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
First posted: 2022-04-06
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.


Eligibility criteria: Inclusion Criteria:

* Males and females of all races between 18 and 65 years of age
* Hypertension defined by two or more properly measured seated blood pressure readings \>130/85 mmHg or currently on antihypertensive medication.
* Obesity will be defined as having a body mass index (BMI) ≥ 30 kg/m2.
* Able and willing to provide informed consent.

Exclusion Criteria:

* Pregnancy or breast feeding
* Current smokers or history of heavy smoking (\>2 packs/day)
* History of alcohol or drug abuse
* Previous allergic reaction to study medications
* Type I diabetes.
* Cardiovascular disease other than hypertension such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy
* History of serious cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack
* History or presence of immunological or hematological disorders
* Impaired renal function
* Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)
* Treatment with any investigational drug in the 1 month preceding the study
* Inability to give, or withdraw, informed consent
* Other factors which in the investigator's opinion would prevent the subject from completing the protocol (i.e., clinically significant abnormalities on clinical, mental examination or laboratory testing or inability to comply with protocol, inability to find IV access)

Primary outcomes:
measure: Endogenous glucose production
timeFrame: During two-step insulin clamp (six hours)
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
References:
Clinical trial NCT00817492: Sleep Disturbances as a Non-Traditional Risk Factor in Chronic Kidney Disease- University of Illinois
Official title: Sleep Disturbances as a Non-Traditional Risk Factor in Chronic Kidney Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Kidney Disease
Keywords: Sleep
CKD
kidney
PSG
polysomnography
Decreased sleep time
Decreased sleep quality
Lead sponsor: University of Chicago
Sponsor class: OTHER
Collaborators: name: University of Illinois at Chicago
First posted: 2009-01-06
Enrollment: 89
Sex: ALL
Minimum age (years): 21
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Renal Clinic patients at The University of Illinois at Chicago Hospital

Brief summary: This study will help determine the relationship between impaired sleep and chronic kidney disease, specifically to determine if sleep disturbances are a risk factor for worsening kidney function.


Eligibility criteria: Inclusion Criteria:

* CKD subjects will be participants in a larger study, CRIC, at the University of Illinois, Chicago
* 30 Healthy controls age and gender matched to 30 CKD subjects, regular bedtimes of at least 6h/night, sedentary lifestyle

Exclusion Criteria:

* Diabetes
* Current or previous dialysis for more than 1 month
* Uncontrolled hypertension
* Heart failure
* Liver disease
* HIV
* Hemoglobin \< 10.5 g/dl
* Treatment with EProcrit, Epogen, or Aranesp
* Bone or organ transplant,
* Use of immunosuppressive drugs within past 6 months
* Current oral contraceptive use
* Current pregnancy
* Chemotherapy for malignancy within past 2 years

Primary outcomes:
measure: Sleep Quality
timeFrame: Sleep Quality was determined after PSG on all subjects were completed
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Illinois at Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Eve Van Cauter, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Illinois at Chicago
name: James Lash, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06489392: Mehri Turki Webbed Neck Classification
Official title: Pterygium Colli Classification of Mehri Turki Imen
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Turner Syndrome
Pterygium Colli
Web Neck
Klippel-Feil Syndrome
Keywords: Webbed neck
Classification
Surgical technique
Lead sponsor: Mohamed Tahar Maamouri University Hospital
Sponsor class: OTHER
First posted: 2024-07-05
Enrollment: 78
Sex: ALL
Minimum age (years): 2
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study is about 78 patients reported in the literature, aged between 2 and 30 years and born with a webbed neck (or pterygium colli)

Brief summary: This study aims to identify all types of congenital neck deformities called " webbed neck ". Through a literature survey, the researcher selected 27 articles describing the surgical treatment of the webbed neck, but without considering the varieties of this deformity. For this reason, the researcher studied all the reported cases from which she developed a classification containing 4 types of webbed necks allowing the use of the most suitable technique to enhance the surgical outcomes.

Detailed description: Through a literature survey of 27 selected articles (from PubMed database and clarivate web of science). The publication years ranged from 1937 to 2020 and the number of patients reported to have undergone surgery was 78 patients.

The webbed neck is a noticeable congenital deformity mainly observed in Turner syndrome. It consists of a bilateral fold extending from the mastoid to the acromion with several distinctions as described in Mehri Turki's webbed neck classification as follows:

Type 1: The fold is maintained by a fibrotic band and the posterior skin is abnormally hairy with a low hairline placement.

Type 2: There is no fibrotic band and the hair abnormality exists as in Type 1

Type 3: There is a fibrotic band and a low posterior hairline but the posterior skin is hairless

Type 4: The fold is maintained by a fibrotic band without hair abnormality

It appears that according to the type of webbed neck, the surgical approach and surgical steps and technique will be adapted to what will be corrected. This classification is therefore crucial to guide surgeons towards the most suitable technique allowing the best results.

Eligibility criteria: Inclusion Criteria:

* Articles with a detailed description of the surgical technique
* Articles reporting post-operative results
* Articles written in English or French

Exclusion Criteria:

* Articles with incomplete descriptions of the webbed neck
* Articles without iconography

Primary outcomes:
measure: Mehri Turki Webbed neck classification
timeFrame: Baseline, pre-sugical procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Nabeul
country: Tunisia
facility: Mohamed Tahar Maamouri University hospital
Study officials:
affiliation: Mohamed Tahar Maamouri University Hospital, Nabeul Tunisia
name: Imen Mehri Turki
role: PRINCIPAL_INVESTIGATOR
References: